Antisense modulation of bcl-x expression
AssigneeIsis Pharmaceuticala, Inc.
InventorsC. Frank Bennett, Nicholas M. Dean, Brett P. Monia, Brian J. Nickoloff, Vivian Q. Zhang
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.
Claims16
An antisense compound 20 to 30 nucleobases in length targeted to nucleobases 876 through 895 or 907 through 926 of a 3′ untranslated region of a nucleic acid molecule encoding a human bcl-x of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.